SIRPB1 and glioma: Our study, for the first time, investigate SIRPB1’s role in glioma’s immune microenvironment, and associates high SIRPB1 levels with poor prognosis and key clinical markers, such as WHO grade, IDH status, and 1p/19q co-deletion.